Evidence map›Paper›PMID 34877613›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study.

Jonas Kuon, Miriam Blasi, Laura Unsöld, Jeannette Vogt, Anja Mehnert, Bernd Alt-Epping, Birgitt van Oorschot, Jochen Sistermanns, Miriam Ahlborn, Ulrike Ritterbusch and 10 more

Abstract readMulticenter Study
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pre-treatment quality of life and survival outcomes in lung cancer patients: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jonas KuonDepartment of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany. Jonas.Kuon@med.uni-heidelberg.de.
Miriam BlasiDepartment of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
Laura UnsöldDepartment of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
Jeannette VogtDepartment of Medicine-2 (Oncology, Gastroenterology, Pulmonology, and Infectious Diseases), and University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, HepatologyLeipzig, Germany.
Anja MehnertDepartment of Medical Psychology and Medical Sociology, University Hospital Leipzig, Leipzig, Germany.
Bernd Alt-EppingDepartment of Palliative Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Birgitt van OorschotInterdisciplinary Department of Palliative Medicine, University Hospital Würzburg, Würzburg, Germany.
Jochen SistermannsDepartment of Radiation Oncology, Kliniken Maria Hilf, Mönchengladbach, Germany.
Miriam AhlbornDepartment of Oncology and Hematology, Klinikum Braunschweig, Braunschweig, Germany.
Ulrike RitterbuschWestdeutsches Tumorzentrum, University Hospital Essen, Essen, Germany.
Susanne StevensDepartment of Internistic Oncology, Kliniken Essen Mitte, Essen, Germany.
Christoph KahlDepartment of Hematology, , Oncology and Palliative Care, Klinikum Magdeburg, Magdeburg, Germany.
Anne RuellanDepartment of Oncology, Hematology and Palliative Care, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
Kathrin MatthiasDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Thomas KubinDepartment of Haematology Oncology and Palliative Care, Klinikum Traunstein, Traunstein, Germany.
Kerstin StahlhutAmbulatory of Haematology Oncology and Palliative Care, Immanuel Klinik Und Poliklinik Rüdersdorf, Rüdersdorf bei Berlin, Germany.
Andrea HeiderDepartment of Medicine 3, Klinikum Leverkusen, Leverkusen, Germany.
Florian LordickDepartment of Medicine 2 (Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Disease), University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Leipzig, Germany.
Michael ThomasDepartment of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
Arbeitsgemeinschaft Palliativmedizin (APM) of the German Cancer Society (DKG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study is to investigate changes over time in quality of life (QoL) in incurable lung cancer patients and the impact of determinants like molecular alterations (MA).

methodsIn a prospective, longitudinal, multicentric study, we assessed QoL, symptom burden, psychological distress, unmet needs, and prognostic understanding of patients diagnosed with incurable lung cancer at the time of the diagnosis (T0) and after 3 (T1), 6 (T2) and 12 months (T3) using validated questionnaires like FACT-L, National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT), PHQ-4, SCNS-SF-34, and SEIQoL.

resultsTwo hundred seventeen patients were enrolled, 22 (10%) with reported MA. QoL scores improved over time, with a significant trend for DT, PHQ-4, and SCNS-SF-34. Significant determinants for stable or improving scores over time were survival > 6 months, performance status at the time of diagnosis, and presence of MA. Patients with MA showed better QoL scores (FACT-L at T1 104.4 vs 86.3; at T2 107.5 vs 90.0; at T3 100.9 vs 92.8) and lower psychological distress (NCCN DT at T1 3.3 vs 5; at T2 2.7 vs 4.5; at T3 3.7 vs 4.5; PHQ-4 at T1 2.3 vs 4.1; at T2 1.7 vs 3.6; at T3 2.2 vs 3.6), but also a worsening of the scores at 1 year and a higher percentage of inaccurate prognostic understanding (27 vs 17%) compared to patients without MA.

conclusionPatients with tumors harboring MA are at risk of QoL deterioration during the course of the disease. Physicians should adapt their communication strategies in order to maintain or improve QoL.

Indexed as

Lung NeoplasmsQuality of LifeHumansPrognosisProspective StudiesSurveys and QuestionnairesLung cancerMolecular alterationsPrognostic awarenessQuality of life

Identifiers

PMID34877613
PMCPMC8857091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.